Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
Go back to Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology| (NASDAQ: NRIX) | Delayed: 18.86 +0.21 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.65 | 52 Week High | $ | |||
| Open | $18.49 | 52 Week Low | $ | |||
| Day High | $19.12 | P/E | N/A | |||
| Day Low | $18.39 | EPS | $ | |||
| Volume | 1,572,009 | |||||
